 |
 |
 |
This electronic newsletter serves as a monthly update on the developments in the field of ophthalmology, issues related to prevention of blindness and new trends in clinical studies in the Middle East and Africa.
MEACO Head Office: P.O.Box 7947, Riyadh 11472, Saudi Arabia
Tel: +966 1 466 1085 - Fax: +966 1 466 1049 - info@meaco.org
WOC2012 Updates
● Free Visa to attend the WOC2012
● A Unique and Fascinating Social Program
● Special Airfares for WOC 2012 Delegates
News
● Download MEACO Calendar
Scientific Articles
comparative study of the contralateral eye: A pilot study
● Oral propranolol for the treatment of periorbital infantile hemangioma: A preliminary report from Oman
Back to top▲
This is the first time that visa application is granted free of charge by the WOC Local host committee to WOC delegates.
Please see visa section for more details on visa application requirements or simply click here for more information.
Remember the deadline for the second bird registration to avail the free visa will expire on 15 December. After this date registration will only be available on site in February 2012, at a higher rate. So register now.
Back to top▲
Back to top▲
Back to top▲
MEACO takes this opportunity to congratulate Dr. Ibrahim and wishes him the best during his tenure at the Alexandria University.
Back to top▲
Back to top▲
.jpg)
comparative study of the contralateral eye: A pilot study
Materials and Methods: The study cohort comprised of 18 subjects with bilateral advanced glaucoma who underwent VISCO-TRAB surgery (VISCO-TRAB group) in the right eye and TRAB (TRAB group) in the left eye. VISCO-TRAB constituted lamellar scleral flap, deep scleral flap dissection with deroofing of Schlemm's canal (SC), viscodilation of SC, penetrating trabeculectomy, peripheral iridectomy, and tight flap closure. All eyes received subconjunctival mitomycin. Success criteria included intraocular pressure (IOP) < 14 mmHg or > 30% lowering of IOP with no devastating complications. A P value less than 0.05 was considered statistically significant.
Results: Mean IOP was significantly lower after VISCO-TRAB compared to TRAB at 1 week and 3 months postoperatively (P<0.05). No eyes lost more than two lines of Snellen acuity. There were more hypotony-related complications after TRAB than VISCO-TRAB surgery. Target IOP was achieved in 83.3% in the VISCO-TRAB group compared to 55.6% in the TRAB group. Conclusion: Combined VISCO-TRAB is effective in reducing IOP to the target level for advanced glaucoma with lower postoperative complications.
Tarek M Eid, Waleed A Tantawy
Middle East Afr J Ophthalmol 2011; Volume: 18, Issue 4, Page: 292-297
Back to top▲
Materials and Methods: Consecutive patients who presented with periorbital capillary hemangioma with vision-threatening lesions were prospectively enrolled in this study between January 2009 and October 2010. All subjects underwent treatment with 2 mg/kg/day oral propranolol. All subjects underwent ocular, systemic, and radiologic evaluations before treatment and at periodic intervals after starting therapy. Side effects from therapy were also evaluated.
Results: Four subjects, between 3 months and 19 months of age, with periorbital hemangioma were enrolled in this study. Two subjects had been previously treated with oral corticosteroids with unsatisfactory response. All subjects had severe ptosis, with the potential for deprivation amblyopia. Three subjects had orbital involvement. After hospital admission, oral propranolol was initiated in all subjects under monitoring by a pediatric cardiologist. Subsequent therapy was performed with periodic out-patient monitoring. All subjects had excellent response to treatment, with regression of periorbital and orbital hemangioma. There were no side effects from therapy. Conclusions: Oral propranolol for periorbital hemangioma was effective in all the four subjects. Oral propranolol may be appropriate for patients who are nonresponsive to intralesional or systemic steroids. In patients with significant orbital involvement and lesions causing vision-threatening complications, oral propranolol can be the primary therapy.
Beena Harikrishna, Anuradha Ganesh, Sana Al-Zuahibi, Samia Al-Jabri, Ahmed Al-Waily, Adil Al-Riyami, Faisal Al-Azri, Feraz Masoud, Abdullah Al-Mujaini
Middle East Afr J Ophthalmol 2011; Volume: 18, Issue 4, Page: 298-303
Back to top▲